

# Delavirdine mesylate

*de-la-VIR-deen*

**Brand Name: Rescriptor**



Delavirdine mesylate, also known as Rescriptor, is a type of antiretroviral drug called a nonnucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself.

## **HIV/AIDS-Related Uses**

---

Delavirdine was approved by the FDA on April 4, 1997, for use with other antiretrovirals in the treatment of HIV infection in adults. Delavirdine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

## **Dosage Information**

---

Delavirdine comes in tablet form and can be taken with or without food. Avoid taking delavirdine within 1 hour of taking didanosine (Videx or ddI) or antacids. Delavirdine 100 mg tablets may be dissolved in water if patients are unable to swallow pills.

## **Recommended Daily Dose**

---

The recommended dose of delavirdine is 400 mg (four 100 mg or two 200 mg tablets) three times a day. Some patients may benefit from different doses of delavirdine. Patients should always take delavirdine as prescribed by their doctor.

## **Contraindications**

---

Individuals who have liver disease should tell a doctor before taking this medicine. Certain medications may affect the functioning of the liver; patients taking these medications should not take delavirdine.

## **Possible Side Effects**

---

Along with its desired effects, delavirdine can cause some unwanted effects, including severe skin rash, blisters, eye inflammation, fever, joint or muscle pain, sores in the mouth, swelling, and difficulty breathing. Delavirdine may also cause agitation; back, leg, or stomach pains; bleeding gums; chills; coma; confusion; dark urine; decreased urine output; depression; difficulty breathing; dizziness; fatigue; fever; general body

swelling; headache; hostility; irritability; loss of appetite; muscle twitching; nausea; nosebleeds; pale skin; rapid weight gain; seizures (convulsions); sore throat; swelling of face, ankles, or hands; unusual tiredness or weakness; vomiting; or yellowing of the eyes or skin.

Other side effects may not be serious and may lessen or disappear with continued use of the medicine. Less serious side effects of this medicine include diarrhea, nausea, vomiting, unusual tiredness, and headache.

Other side effects not listed above may also occur in some patients. If you notice any other effects, check with your doctor.

## **Drug and Food Interactions**

---

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

## **Clinical Trials**

---

For information on clinical trials that involve Delavirdine mesylate, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box, enter: Delavirdine mesylate AND HIV Infections.

## **Manufacturer Information**

---

Rescriptor  
Pfizer Inc  
235 East 42nd Street  
New York, NY 10017-5755  
(800) 438-1985

Delavirdine mesylate  
Pfizer Inc  
235 East 42nd Street  
New York, NY 10017-5755  
(800) 438-1985

# ***Delavirdine mesylate***



## **For More Information**

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: [http://aidsinfo.nih.gov/live\\_help](http://aidsinfo.nih.gov/live_help) Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET